Eli Lilly's GLP-1 Drugs Show Rapid Growth Amid Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, saw sales increase by 99% and 175% in 2025, respectively, contributing to 56% of the company's total revenue, indicating strong market demand but also highlighting the risks of product dependency.
- Competitive Pressure: As Mounjaro and Zepbound face future generic competition, their revenues and profits are expected to decline significantly, posing a threat to Eli Lilly's long-term growth, especially with competitors actively seeking alternative drugs.
- Valuation Risks: With a price-to-earnings ratio of 45 and a meager dividend yield of 0.6%, Eli Lilly's stock appears overvalued, suggesting that if the performance of its GLP-1 drugs falls short of expectations, the stock price could face substantial downside risk.
- Pfizer's Investment Opportunity: Despite setbacks in GLP-1 drug development, Pfizer offers a 6.3% dividend yield and a more reasonable P/E ratio of around 20, while demonstrating potential for long-term growth through acquisitions and partnerships, making it a more attractive option for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1022.020
Low
950.00
Averages
1192
High
1500
Current: 1022.020
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drugs Show Rapid Growth Amid Concerns
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, saw sales increase by 99% and 175% in 2025, respectively, contributing to 56% of the company's total revenue, indicating strong market demand but also highlighting the risks of product dependency.
- Competitive Pressure: As Mounjaro and Zepbound face future generic competition, their revenues and profits are expected to decline significantly, posing a threat to Eli Lilly's long-term growth, especially with competitors actively seeking alternative drugs.
- Valuation Risks: With a price-to-earnings ratio of 45 and a meager dividend yield of 0.6%, Eli Lilly's stock appears overvalued, suggesting that if the performance of its GLP-1 drugs falls short of expectations, the stock price could face substantial downside risk.
- Pfizer's Investment Opportunity: Despite setbacks in GLP-1 drug development, Pfizer offers a 6.3% dividend yield and a more reasonable P/E ratio of around 20, while demonstrating potential for long-term growth through acquisitions and partnerships, making it a more attractive option for investors.
See More
Novo Nordisk Posts Record Low Stock Performance Amid Competitive Pressures
- Stock Plunge: Novo Nordisk's stock has plummeted 37% in February, marking its worst performance ever, primarily due to Eli Lilly's strengthening leadership in the obesity drug market, which has shaken investor confidence.
- Profit Downgrade: The company projected a worse-than-expected profit decline for 2026 due to pricing pressures from a deal with the U.S. government and patent expirations, leading to a 15% drop in early February.
- Clinical Trial Setback: Recent trial data indicated that Novo's next-gen weight loss therapy CagriSema is less effective than Eli Lilly's Zepbound, exacerbating market concerns about Novo's future product viability.
- Analyst Rating Divergence: Despite Novo's shares hitting their lowest level since mid-2021, some analysts remain bullish, arguing that the stock is undervalued and that the company still possesses a robust pipeline and strong financials.
See More
Nvidia Reports Strong Earnings but Shares Decline
- Earnings Beat: Nvidia's fourth-quarter results surpassed revenue and profit expectations, indicating sustained demand for its AI compute platforms; however, the stock price sharply declined, reflecting investor skepticism about the sustainability of high expectations.
- Cautious Market Reaction: Despite Nvidia's strong performance, Wall Street's muted response highlights a shift in focus from headline earnings to deeper concerns regarding long-term growth, capital returns, and competitive dynamics in the AI sector.
- Increased Competitive Pressure: As rival AI hardware efforts gain traction, investors are increasingly concerned about future spending patterns and competition from alternative AI chip designs, which has pressured broader technology stocks and underscored the fragility of the AI-led market rally.
- Significant Industry Impact: Nvidia's pullback not only affected its own stock but also weighed heavily on the semiconductor sector, contributing to sluggish performance among major tech benchmarks late in the week, indicating a waning confidence in AI-related stocks.
See More
Slop Bowls Are a Thing of the Past. We Explore the Future of Lunch: The Wrap
- New Menu Item: Sweetgreen is introducing wraps at select locations, expanding its menu beyond salads.
- Brand Identity: The fast-casual chain is known for its high-quality greens and aims to innovate its offerings while maintaining its brand identity.
See More
Jim Cramer Highlights AI Investment Opportunities
- AI Investment Focus: Jim Cramer emphasized the significance of AI stocks during the Investing Club meeting, particularly highlighting Nvidia as the gold standard in AI computing, with its stunning quarterly results reinforcing the notion of an ongoing Fourth Industrial Revolution.
- Corning's New Strategy: After visiting its Kentucky factory, Jim learned about Corning's ambition to enhance data center connectivity by replacing copper with fiber optics, indicating a strong growth trajectory in the data center market that could drive future company performance.
- Eaton's Acquisition Plans: Eaton's strategy to spin off its eMobility unit and acquire Boyd Thermal aims to bolster its competitive edge in liquid cooling technology, which is crucial for managing heat in AI chips, thereby enhancing its market position.
- Alphabet and Amazon Performance: Alphabet stands out in the AI sector with its strong YouTube and cloud computing divisions, while Amazon's AWS cloud business is accelerating, although both face capital expenditure pressures, they are still viewed as solid long-term investment opportunities.
See More
Positive Opinion for Olumiant in Treating Severe Alopecia Areata in Adolescents
- Clinical Trial Results: The Phase 3 BRAVE-AA-PEDS study demonstrated that 42% of patients with severe alopecia areata achieved over 80% scalp hair coverage at 36 weeks, indicating Olumiant's efficacy in adolescents and potentially providing a new treatment option for this vulnerable population.
- Regulatory Progress: The European Medicines Agency (EMA) has issued a positive opinion for Olumiant's use in treating severe alopecia areata in adolescents aged 12 to under 18, with a final decision expected in the next one to two months, further facilitating market access for the drug.
- Significant Treatment Effects: The study revealed that 36.5% of patients achieved near-complete scalp hair regrowth within 36 weeks, with 50% experiencing successful eyebrow regrowth and 42.9% achieving eyelash regrowth, highlighting its potential to improve patients' quality of life.
- Broad Market Prospects: As the first JAK inhibitor approved by both EMA and FDA for adult severe alopecia areata, the expansion of Olumiant's application to adolescents will further solidify Lilly's leadership in the treatment of autoimmune diseases, addressing the urgent market demand for effective therapeutic options.
See More
Eli Lilly's GLP-1 Drugs Show Rapid Growth Amid Concerns
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, saw sales increase by 99% and 175% in 2025, respectively, contributing to 56% of the company's total revenue, indicating strong market demand but also highlighting the risks of product dependency.
- Competitive Pressure: As Mounjaro and Zepbound face future generic competition, their revenues and profits are expected to decline significantly, posing a threat to Eli Lilly's long-term growth, especially with competitors actively seeking alternative drugs.
- Valuation Risks: With a price-to-earnings ratio of 45 and a meager dividend yield of 0.6%, Eli Lilly's stock appears overvalued, suggesting that if the performance of its GLP-1 drugs falls short of expectations, the stock price could face substantial downside risk.
- Pfizer's Investment Opportunity: Despite setbacks in GLP-1 drug development, Pfizer offers a 6.3% dividend yield and a more reasonable P/E ratio of around 20, while demonstrating potential for long-term growth through acquisitions and partnerships, making it a more attractive option for investors.
See More
Novo Nordisk Posts Record Low Stock Performance Amid Competitive Pressures
- Stock Plunge: Novo Nordisk's stock has plummeted 37% in February, marking its worst performance ever, primarily due to Eli Lilly's strengthening leadership in the obesity drug market, which has shaken investor confidence.
- Profit Downgrade: The company projected a worse-than-expected profit decline for 2026 due to pricing pressures from a deal with the U.S. government and patent expirations, leading to a 15% drop in early February.
- Clinical Trial Setback: Recent trial data indicated that Novo's next-gen weight loss therapy CagriSema is less effective than Eli Lilly's Zepbound, exacerbating market concerns about Novo's future product viability.
- Analyst Rating Divergence: Despite Novo's shares hitting their lowest level since mid-2021, some analysts remain bullish, arguing that the stock is undervalued and that the company still possesses a robust pipeline and strong financials.
See More
Nvidia Reports Strong Earnings but Shares Decline
- Earnings Beat: Nvidia's fourth-quarter results surpassed revenue and profit expectations, indicating sustained demand for its AI compute platforms; however, the stock price sharply declined, reflecting investor skepticism about the sustainability of high expectations.
- Cautious Market Reaction: Despite Nvidia's strong performance, Wall Street's muted response highlights a shift in focus from headline earnings to deeper concerns regarding long-term growth, capital returns, and competitive dynamics in the AI sector.
- Increased Competitive Pressure: As rival AI hardware efforts gain traction, investors are increasingly concerned about future spending patterns and competition from alternative AI chip designs, which has pressured broader technology stocks and underscored the fragility of the AI-led market rally.
- Significant Industry Impact: Nvidia's pullback not only affected its own stock but also weighed heavily on the semiconductor sector, contributing to sluggish performance among major tech benchmarks late in the week, indicating a waning confidence in AI-related stocks.
See More
Slop Bowls Are a Thing of the Past. We Explore the Future of Lunch: The Wrap
- New Menu Item: Sweetgreen is introducing wraps at select locations, expanding its menu beyond salads.
- Brand Identity: The fast-casual chain is known for its high-quality greens and aims to innovate its offerings while maintaining its brand identity.
See More
Jim Cramer Highlights AI Investment Opportunities
- AI Investment Focus: Jim Cramer emphasized the significance of AI stocks during the Investing Club meeting, particularly highlighting Nvidia as the gold standard in AI computing, with its stunning quarterly results reinforcing the notion of an ongoing Fourth Industrial Revolution.
- Corning's New Strategy: After visiting its Kentucky factory, Jim learned about Corning's ambition to enhance data center connectivity by replacing copper with fiber optics, indicating a strong growth trajectory in the data center market that could drive future company performance.
- Eaton's Acquisition Plans: Eaton's strategy to spin off its eMobility unit and acquire Boyd Thermal aims to bolster its competitive edge in liquid cooling technology, which is crucial for managing heat in AI chips, thereby enhancing its market position.
- Alphabet and Amazon Performance: Alphabet stands out in the AI sector with its strong YouTube and cloud computing divisions, while Amazon's AWS cloud business is accelerating, although both face capital expenditure pressures, they are still viewed as solid long-term investment opportunities.
See More
Positive Opinion for Olumiant in Treating Severe Alopecia Areata in Adolescents
- Clinical Trial Results: The Phase 3 BRAVE-AA-PEDS study demonstrated that 42% of patients with severe alopecia areata achieved over 80% scalp hair coverage at 36 weeks, indicating Olumiant's efficacy in adolescents and potentially providing a new treatment option for this vulnerable population.
- Regulatory Progress: The European Medicines Agency (EMA) has issued a positive opinion for Olumiant's use in treating severe alopecia areata in adolescents aged 12 to under 18, with a final decision expected in the next one to two months, further facilitating market access for the drug.
- Significant Treatment Effects: The study revealed that 36.5% of patients achieved near-complete scalp hair regrowth within 36 weeks, with 50% experiencing successful eyebrow regrowth and 42.9% achieving eyelash regrowth, highlighting its potential to improve patients' quality of life.
- Broad Market Prospects: As the first JAK inhibitor approved by both EMA and FDA for adult severe alopecia areata, the expansion of Olumiant's application to adolescents will further solidify Lilly's leadership in the treatment of autoimmune diseases, addressing the urgent market demand for effective therapeutic options.
See More
